ERBB2 and breast carcinoma: A synergistic effect of roblitinib with trastuzumab was observed in PDX/PDO models originating from non-pCR HER2-positive breast cancer tissue after anti-HER2 based neoadjuvant therapy (intrinsic resistance) and liver metastasis of HER2-positive breast cancer tissue (acquired resistance).